{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Brazil Medical Instruments & Supplies news", "home_page_url": "https://sharemaestro.com/newsreel/br/healthcare/medical-instruments-supplies/", "feed_url": "https://sharemaestro.com/newsreel/br/healthcare/medical-instruments-supplies/feed.json", "description": "Latest Medical Instruments & Supplies company headlines from Brazil, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:53fb05c36057c573566bfb7e8af0d607cf6f9c966d679ea9638ae9e2d7b9b533", "url": "https://finance.yahoo.com/markets/stocks/articles/nvst-buy-earnings-rebound-valuation-130400554.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/nvst-buy-earnings-rebound-valuation-130400554.html", "title": "Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median?", "content_text": "Envista Holdings Corporation NVST is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case. The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for execution setbacks even as operating momentum improves. NVST's Earnings Recovery Supports the Bull Case Adjusted earnings were 41 cents per share in the second quarter of 2026, up 57.7% year over year. Operating profit rose 73.4% to $80.3 million, while the operating margin expanded 420 basis", "date_published": "2026-08-13T13:04:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:53f40eb0183ab4ac381dc42e53f0c95c6e02c2bfca22e0e4a52bf13451e71d1a", "url": "https://finance.yahoo.com/markets/stocks/articles/omnicell-raises-2026-eps-outlook-125500578.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/omnicell-raises-2026-eps-outlook-125500578.html", "title": "Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins", "content_text": "Omnicell, Inc. OMCL raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund. The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive to hospital purchasing timelines. Omnicell Lifted Its 2026 Earnings Outlook Omnicell now expects adjusted earnings of $2.15-$2.30 per share for 2026, up from $1.80-$2.00 previously. Non-GAAP EBITDA guidance increased to $175-$185 million. Second-quarter adjusted earnings reached 94 c", "date_published": "2026-08-13T12:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1AX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1AX34", "name": "Baxter International Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1951509f-3248-4828-b63d-b3bf1bca14ee/"}]}}, {"id": "source:c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return declining 16.1%. The recent 7 day share price return of 8.95% and 3 year total shareholder return of 30.9% suggest longer term holders have still seen gains even as short term momentum has been pressured by concerns about slower procedures and growing competition. If you are looking beyond Intuitive Surgical for other ideas in medical robotics and automation, it could be a useful moment to scan the market using the 39 robotics and automation stocks Bulls point to Intuitive Surgical's premium multiple, strong Q2 beat and large installed base. Bears focus on slowing U.S. procedures, pricing questions and new rivals. Which side does the current valuation evidence support? Most Popular Narrative: 36.4% Undervalued Based on the most followed narrative, Intuitive Surgical's fair value sits at $630.48 compared with the last close of $401.23. That gap is what powers the bullish story that many investors are watching closely. I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone. Wiser heads in the club prevailed and we started a position at around $48 a share and continued to add to the position. In 2005 ISRG was trading at over $200 a share and I was getting nervous. I convinced the club to place a trailing stop on ISRG. The price continued to increase and reached $393 a share. Then ISRG stock price started to drop it got as low as $200 a share. Our trailing stop worked like a charm we were sold out of the club position at just above $360 a share. I tried to convince the club to reinvest in ISRG at $200 a share; they decided not to, but I did. I describe it as riding the lightning. I have bought and sold ISRG at least twice since then and watched the share price increase to over $1000 a share twice before doing a 3 for 1 stock split, first in 2017 and then again in 2021. Did I mention no debt? Story Continues Read the complete narrative. Want to see what kind of revenue growth, profit margins and future earnings multiple sit behind that $630.48 fair value? The narrative pulls together long term profitability, high margins and a premium future P/E assumption into one cohesive pricing blueprint that is very different to the current $401.23 share price. Result: Fair Value of $630.48 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Intuitive Surgical still faces real risks if U.S. procedure growth slows further or if rival robotic platforms lead hospitals to reassess their spending plans. Find out about the key risks to this Intuitive Surgical narrative. Another View on Intuitive Surgical's Valuation The community narrative points to a fair value of $630.48 for Intuitive Surgical, which implies the stock is 36.4% undervalued versus the current $401.23 price. However, the current P/E of 45.2x is well above the US Medical Equipment industry at 26.3x, the peer average at 28.8x and even the fair ratio of 35.1x. That kind of premium can signal quality, but it also raises the risk that any disappointment hits the share price harder than expected. To see how that rich P/E stacks up against the underlying numbers and where the market could move closer to the fair ratio, take a closer look at the valuation breakdown in the See what th", "date_published": "2026-08-12T21:13:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:c6eafdfc22d548b9106fb663c201452672aac2c3d6904920bde827aebe3c9ab0", "url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "title": "ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?", "content_text": "Intuitive Surgical ISRG has faced a moderation in U.S. procedure growth during the first half of 2026, but management's commentary suggests the slowdown is more likely a temporary demand-timing issue than evidence of a structural deterioration. U.S. da Vinci procedures grew 12% in the second quarter, down from 14% in the first quarter. da Vinci procedure growth was 17% in the fourth quarter of 2025. Management pointed to a modest adverse impact from the expiration of enhanced ACA premium subsidies. Customer feedback indicated that changes in insurance coverage and premium dynamics affected the timing of patient visits, particularly for procedures that can be postponed. Intuitive Surgical also stated that the underlying disease burden remains unchanged, implying that deferred benign procedures should eventually return as patients re-enter the healthcare system. Management also noted that the procedure moderation likely reflected a combination of ACA-related effects and the \"law of large numbers,\" rather than a single factor. The distinction between deferrable and non-deferrable procedures was particularly important, with the former showing greater moderation. For the second half, investors should nevertheless expect some pressure on reported growth. Intuitive Surgical maintained its 2026 da Vinci procedure growth forecast of 13.5-15.5%, expecting performance toward the midpoint. Management flagged tougher U.S. comparisons in the third quarter, alongside seasonal effects internationally, while incorporating ACA-related patient behavior into its outlook. At this stage, the slowdown does not appear structural. U.S. utilization still increased 3%, while system placements rose 24%, and management said ACA concerns had not affected the capital pipeline. Strong adoption of da Vinci 5 continues to support upgrades and capacity expansion. The key risk is the duration of deferred procedures, rather than weakening underlying demand for robotic surgery. Peer Updates Globus Medical's GMED robotic platform faced a softer Enabling Technologies quarter, with revenues declining 26% year over year to $26.1 million. The company attributed the decline primarily to its shift toward greater flexibility in capital acquisition, rather than explicitly citing ACA premium-subsidy changes. Despite lower capital revenues, demand for Excelsius technology remained healthy. EGPS and eHub units deployed through sales, leases or rentals rose 25% year over year, while robotic utilization surpassed 137,000 procedures. Management also acknowledged tougher second-half comparisons and remained cautious on its outlook because of Enabling Technologies' strategy shift and Nevro integration. Story Continues Stereotaxis' STXS robotic business continues to face commercialization and procedure-related headwinds, but management did not specify any headwind from ACA premium subsidy expiration. Revenues declined 13% year over year to $7.7 million, partly because no robotic system was delivered during the quarter. Management also cited \"general pressure on procedures\" as the company transitions from Johnson & Johnson and ramps up its own catheter manufacturing. Catheter supply constraints remain a bigger near-term bottleneck as demand exceeds available production, limiting shipments despite customer orders. STXS' robotic growth is currently constrained more by product availability, hospital adoption, and procedure volumes than by any clearly identified impact from ACA subsidy changes. ISRG's Price Performance, Valuation and Estimates Shares of ISRG have lost 29.2% so far this year compared with a 6.8% decline of the industry.Zacks Investment Research Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 34.95X, above the industry average. But it is significantly lower than its five-year median of 69.05X. ISRG carries a Value Score of D.Zacks Investment Research Image Source: Zacks Investment Resea", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:1a2f40c9baba16791fafa02e496aab8f277ad40842ea3d434963cc20daa39c8d", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-apos-competitors-face-153642167.html", "external_url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-apos-competitors-face-153642167.html", "title": "Intuitive Surgical's Competitors Face Challenges That Limit Long-Term Appeal, Oppenheimer Says", "content_text": "Intuitive Surgical's (ISRG) competitors face unique workflow challenges and real estate issues that impact their long-term appeal, while customized price-volume contracts complicate competitors' return on investment and its flexible per-click model allows growth opportunities in Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T15:36:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:b0259a224d0109f83881d0016c1981c58205f0f8dc852f77da3bc09682efd352", "url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "external_url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "title": "Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too.", "content_text": "Key Points The robotic surgery specialist has over 12,000 installed systems globally. Right now, it's facing some headwinds, but it also has a lot going for it. The Baron Health Care Fund sees Intuitive Surgical as full of promise.10 stocks we like better than Intuitive Surgical \u203a If you're not familiar with Intuitive Surgical(NASDAQ: ISRG), know this: It's a massive robotic surgical systems specialist, with a recent market value topping $135 billion. That market value was quite a bit higher not so long ago, though -- because while the stock has averaged annual gains of 17% over the past decad", "date_published": "2026-08-12T13:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:0f730957215724fed72c0676028ca481b671a1c667c1d0f654137bf7849ad1c6", "url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "title": "If You Invested $1000 in Intuitive Surgical, Inc. 10 Years Ago, This Is How Much You'd Have Now", "content_text": "For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in Intuitive Surgical, Inc. (ISRG) ten years ago? It may not have been easy to hold on to ISRG for all that time, but if you did, how much would your investment be worth today? Intuitive Surgical, Inc.'s Business In-Depth ", "date_published": "2026-08-12T12:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulatory surgery centers, and argued that customized price-volume contracts make it hard for rivals to show a compelling return on investment. Bank of America Securities issued a Buy rating as well. The stock has now drawn several upgrades in about three weeks, following UBS and Morgan Stanley in late July, both of which argued the selloff had gone too far. The stock still has significant ground to recover. Shares are down over 30% year to date. Second-quarter adjusted EPS of $2.80 came in above the $2.51 consensus. View Comments", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:75888f862fb99d1fc168057a6c9e61e2eacc5651a5ffc663765ed1e846246f77", "url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "external_url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "title": "Align Technology Prevails in China Patent Infringement Action", "content_text": "Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China issued a judgment in its favor, in a patent infringement action against Angelalign Technology's operating subsidiaries in China.The company provides an orthodontic treatment system Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T08:19:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:489156e89e7017d5e7f39c2ba068798752e619ef2a204d2a699011b5ae4515aa", "url": "https://finance.yahoo.com/markets/stocks/articles/recall-hit-outlook-bigger-payout-023350160.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/recall-hit-outlook-bigger-payout-023350160.html", "title": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?", "content_text": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed's broader sleep-health and digital platform story may be. Next, we'll examine how the ventilator sales suspension and softer fiscal 2027", "date_published": "2026-08-12T02:33:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "R1MD34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "R1MD34", "name": "ResMed Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a18efe09-40e4-4818-af70-795a0b494dba/"}]}}, {"id": "source:62c2b790a504d8ab741a3bfe66a712bd019051a2be167b5862c1efdcc1ff53a7", "url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-004700024.html", "external_url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-004700024.html", "title": "Align Technology Prevails in China Patent Infringement Action Against Angelalign", "content_text": "SAN JOSE, Calif. & TEMPE, Ariz., August 12, 2026--(BUSINESS WIRE)--Align Technology, Inc. (\"Align\") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign\u00ae System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China (\"Angel\") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align's patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products manufactured and sold using the accused technology also infringe Align's patent. Angel may appeal the judgment to the Supreme People's Court. The deadline for filing an appeal has not yet expired. The court ordered Angel to cease using the patented technology and to stop manufacturing and selling the infringing products in China and awarded Align RMB 10 million in damages. While the ruling remains subject to appeal, Align believes the decision further reinforces the strength of its intellectual property portfolio and ongoing commitment to protecting its innovations globally. The ruling follows other recent developments in Align's patent-enforcement actions against Angel. In February 2026, the Unified Patent Court (\"UPC\") issued a preliminary injunction requiring Angel to cease infringement of Align's patented ClinCheck\u00ae Live Update technology, a decision that was subsequently upheld on appeal. In July 2026, the U.S. International Trade Commission (\"ITC\") conducted an evidentiary hearing concerning five patents asserted by Align against Angel. Align expects that the ITC will make its initial determination regarding the merits of Align's claims in November 2026. Align also continues to pursue additional patent infringement actions against Angel affiliates in China and Europe. \"Align has made significant long-term investments in innovation and in the Chinese market,\" said Joe Hogan, president and chief executive officer of Align Technology. \"We respect the role of China's courts in protecting intellectual property rights and are encouraged by this decision. Protecting intellectual property is essential to sustaining that innovation and ensuring continued investment in technologies that benefit doctors and patients. This decision reinforces the value and strength of Align's intellectual property portfolio and the significant investments we have made to develop industry-leading technologies. We remain committed to supporting fair competition, advancing innovation, and protecting our intellectual property rights while competing in the marketplace.\" Story Continues Align's Cutting-Edge Global Operations As a global leader in digital orthodontics and restorative dentistry with nearly 23.5 million Invisalign\u00ae patients treated worldwide, Align continues to transform the orthodontic industry through its global operations, advanced manufacturing capabilities, and doctor-directed treatment planning. Align's operations span the Americas, EMEA, and APAC regions, with clinical treatment planning centers in Costa Rica, Poland, China (Chengdu), Spain, France, Germany, and Japan. The company's global aligner manufacturing operations includes world-class facilities in Juarez, Mexico; Wroclaw, Poland; and Ziyang, China; Vienna, Austria; San Jose, CA; and a new aligner manufacturing facility coming online in 2027 in Hyderabad, India; together forming the backbone of the world's largest 3D printing netwo", "date_published": "2026-08-12T00:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:5e24f116e94ed703b1d3d5525dad9a6595c1e7a17622c24056a09e8b6634a74d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "title": "Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?", "content_text": "Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns about slowing domestic procedure growth. Worldwide procedures, da Vinci and Ion combined, grew around 16% compared to the prior year period, with Da Vinci procedures growing approximately 15% and Ion procedures growing approximately 36%. These trends disappointed investors accustomed to the company's historica", "date_published": "2026-08-10T21:04:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "content_text": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 16%, including 15% growth in da Vinci procedures and 36% growth in Ion procedures. Recurring revenues also climbed 19% to $2.47 billion, representing 85% of total revenues. Utilization remained healthy, with da Vinci system utilization increasing 3% and Ion utilization rising 11%. The second-quarter performance remained strong, although revenue growth moderated from 23% in the first quarter. U.S. da Vinci procedure growth slowed to 12% from 14% in the first quarter, reflecting some moderation in deferrable procedures. However, the company continued to deliver strong international growth and higher utilization from its expanding da Vinci 5 installed base. With the premium multiple sitting well above the broader industry, the real test for investors is whether management's forward guidance justifies paying up today. ISRG's Premium Valuation Raises ConcernZacks Investment Research Image Source: Zacks Investment Research Forward Guidance Signals Sustained Growth Potential Management's updated outlook remains constructive for investors weighing the premium multiple. Intuitive Surgical maintained its 2026 da Vinci procedure-growth forecast at 13.5-15.5%, with growth expected to be closer to the midpoint. General surgery in the United States and procedures outside urology internationally are expected to remain the primary drivers. The outlook incorporates risks from U.S. patient behavior, obesity drugs, China tender volumes and competition, European capital pressures and Japan's recovery. Importantly, the company raised its 2026 adjusted gross-margin outlook to 68-69% from 67.5-68.5%. This suggests that product cost reductions and operating leverage are increasingly offsetting higher freight and semiconductor-memory costs, as well as the favorable margin impact of faster growth in newer platforms. Operating expenses are now expected to grow 11-13%, with R&D continuing to expand faster than SG&A as Intuitive Surgical prioritizes innovation. Story Continues The guidance therefore points to sustained growth rather than a material deterioration in fundamentals, although the slower U.S. procedure trajectory remains a factor investors should monitor. The Zacks Consensus Estimate for 2026 earnings is pegged at $10.74 per share, implying solid 20.3% year-over-year growth. Intuitive Surgical currently carries a Zacks Rank #3 (Hold), reflecting a neutral stance. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Intuitive Surgical, Inc. Price and ConsensusIntuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote Recent Product and Pipeline Developments Intuitive Surgical's product ecosystem continues to provide multiple avenues for future growth. The company placed 468 da Vinci systems in the second quarter, up 18% year over year, with 246 being da Vinci 5 systems. Its da Vinci 5 installed base exceeded 1,700 systems and has been used by more than 15,000 surgeons. Meanwhile, SP procedures surged 61%, supported by expanded indications, new instruments and broader geographic adoption. Ion remains an important growth platform, with procedures rising 36% to 48,000. The company is advancing its ROSE and EBUS programs, while a next-generation flexible robotic endoscope for gastrointestinal applications has been submitted for FDA 510(k) clearance. Intuitive Surgical i", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:1f3a1d2d0e41f5a6089112952037dac0c453a7c78b4d75fbfa04ceabaf7c7c68", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "content_text": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differentiated design and broader surgical portfolio into meaningful market share, and even challenge Intuitive Surgical (ISRG) in the process.Is Microbot Medical Inc. (MBOT) the Best Rising Penny Stock to Buy According to Analysts? Bull Case for Johnson & Johnson (JNJ) OTTAVA's most compelling feature is its table-integrated architecture. Johnson & Johnson (NYSE:JNJ) stated that the robotic arms are incorporated directly into the operating table, which allows the system to occupy 30% to 50% less space than traditional boom- and cart-mounted systems. The company believes this design could make robotic surgery accessible to operating rooms that previously could not accommodate a larger platform. That gives Johnson & Johnson (NYSE:JNJ) a potentially differentiated selling point among hospitals focused on operating-room capacity and workflow efficiency. The FDA authorized OTTAVA for multiple upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair. Johnson & Johnson (NYSE:JNJ) will commercially launch the OTTAVA system with select customers in the United States to focus on early customer success and simultaneously advance the technology into additional regulatory jurisdictions and indications gradually. In addition, it has an ongoing U.S. clinical trial for OTTAVA in inguinal hernia procedures. The selective launch is strategically sensible because robotic surgery systems require several factors for their smooth functioning in addition to regulatory authorization, including training for surgeons and operating-room staff, integration of the system into existing workflows, and establishing procedure volumes sufficient to justify the investment. With such a measured rollout, Johnson & Johnson (NYSE:JNJ) has time to collect real-world feedback, improve training, and refine the platform before attempting a broader commercial expansion. J&J also brings advantages that smaller robotic-surgery challengers may lack. Its surgical portfolio already includes wound-closure products, stapling systems, instruments, and other operating-room technologies. That existing presence could provide commercial access to hospitals and surgeons as the company introduces OTTAVA. However, the degree to which J&J can translate those relationships into robotic-system placements remains unproven. Story Continues The authorization also adds a new growth opportunity to Johnson & Johnson's (NYSE:JNJ) MedTech business. The segment generated $8.93 billion in second-quarter 2026 sales, up 4.5% on a reported basis and 3.6% on an adjusted operational basis. While OTTAVA is unlikely to materially affect Johnson & Johnson's (NYSE:JNJ) near-term financial results during a limited rollout, successful adoption could eventually strengthen the company's position in higher-growth surgical technology. Why Intuitive Surgical Remains Difficult to Displace Although OTTAVA gives Johnson & Johnson (NYSE:JNJ) a credible platform, Intuitive Surgical (NASDAQ:ISRG) enters the competitive battle from a position of considerable strength. Intuitive had an installed base of 11,710 da Vinci systems at the end of the second quarter of 2026, up 12% from the previous year. The company placed 468 da Vinci systems during the quarter, including 246 da Vinci 5 systems, compared with 395 total systems and 180 da ", "date_published": "2026-08-10T12:42:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:a7fce7bb8cf3281d6f50dd3243582755395fec6f6d49690fa201073af5e8f1d0", "url": "https://finance.yahoo.com/markets/stocks/articles/resmed-rmd-stock-may-31-101225136.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/resmed-rmd-stock-may-31-101225136.html", "title": "Resmed\u2019s stock falls by 7% on soft FY27 outlook", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while uncert", "date_published": "2026-08-10T10:12:02+00:00", "authors": [{"name": "Medical Device Network"}], "tags": ["Earnings", "R1MD34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "R1MD34", "name": "ResMed Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a18efe09-40e4-4818-af70-795a0b494dba/"}]}}, {"id": "source:ba0d67fee27205d645a1b06dcd2e7dd93826039a4894bb643f53aaa14cfc74cf", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "title": "Intuitive Surgical (ISRG) Stock Looks Fairly Valued Despite Its 33% Slide", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Intuitive Surgical stock has had a difficult start to 2026, with the share price down 32.6% year to date, while the Discounted Cash Flow (DCF) intrinsic value estimate now points to a level that is broadly in line with where the market is pricing the company. The year to date decline of 32.6% raises the question of whether recent weakness is now fully reflected in the share price. Management commentary around durable demand for platforms like da Vinci 5 ", "date_published": "2026-08-09T02:08:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:d4bf15b2230cbd7b388ab35f957cf11c1c7f0b4d4233cedd8aa0b69c8eb232a6", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "title": "What Do Intuitive Surgical (ISRG) Bylaw Changes Mean For Shareholders?", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Intuitive Surgical (NasdaqGS: ISRG) has approved amendments to its bylaws, updating shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals. The changes affect how investors can engage with the company on governance matters and may influence future proxy conte", "date_published": "2026-08-09T01:12:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "I1SR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1SR34", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec13d75f-7638-42ed-930f-06fce65f6604/"}]}}, {"id": "source:3570d860112cd357828210b3a3e36b2e47a4c5a4bfd06c161b678afd17bcfdce", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1oMC1xRFFacHpqN2RibHZmYmxjVjlySXZ2TThlQW9uLU1HWTZ5QW1iTUZWVjBrb2JHNjUybFZGTTJLN2RpQ2F4OUN6eUFVYllnQkE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1oMC1xRFFacHpqN2RibHZmYmxjVjlySXZ2TThlQW9uLU1HWTZ5QW1iTUZWVjBrb2JHNjUybFZGTTJLN2RpQ2F4OUN6eUFVYllnQkE?oc=5", "title": "BDR Baxter International - B1AX34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "content_text": "BDR Baxter International - B1AX34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "date_published": "2021-04-27T18:07:11+00:00", "authors": [{"name": "Investidor10"}], "tags": ["Market update", "B1AX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1AX34", "name": "Baxter International Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1951509f-3248-4828-b63d-b3bf1bca14ee/"}]}}, {"id": "source:a74d9fd7a3e598db2b3a667ef6ec4f5bda00225465911bb9d22a47759d17fbb7", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFAzVFZwdDZnekdWcS1sdFI3U3J6dG5ONUg0YlNGTkJ0WWJ2bHZEcUU5cUg1ZHFleGFQMHJ2YkFMWGlQQzVMRjVveXl3OF9DTTlwcWc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFAzVFZwdDZnekdWcS1sdFI3U3J6dG5ONUg0YlNGTkJ0WWJ2bHZEcUU5cUg1ZHFleGFQMHJ2YkFMWGlQQzVMRjVveXl3OF9DTTlwcWc?oc=5", "title": "BDR Align Technology - A1LG34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "content_text": "BDR Align Technology - A1LG34 - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "date_published": "2021-03-18T17:05:48+00:00", "authors": [{"name": "Investidor10"}], "tags": ["Market update", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}]}